DEA Revokes Naturopath Registration After State License Loss
Published Date: 6/24/2026
Notice
Summary
Amanda Ward, a naturopathic doctor from California, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t respond to the DEA’s notices or ask for a hearing, so her registration was officially revoked as of May 31, 2026. This means she can’t prescribe or manage controlled drugs anymore, affecting her medical practice and patients.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for Amanda Ward
The Drug Enforcement Administration revoked Amanda Ward, N.D.'s DEA Certificate of Registration No. MW1889534, so she can no longer prescribe, dispense, or otherwise handle controlled substances. The Order is effective July 24, 2026; the record also notes her DEA registration expired on May 31, 2026 and that she surrendered her California naturopathic license on April 23, 2024 (license expiration listed as August 31, 2025).
DEA Denies Ward's Renewal and New California Registrations
The DEA order also denies any pending applications by Amanda Ward to renew or modify her DEA registration and denies any other pending application for additional registration in California. That denial is part of the same final Order effective July 24, 2026.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-12654 — Schedules of Controlled Substances: Temporary Placement of O-Desmethyltramadol in Schedule I
Starting July 24, 2026, O-desmethyltramadol (also called O-DSMT) will be temporarily placed in Schedule I, meaning it’s treated like the most tightly controlled drugs. This affects anyone who makes, sells, studies, or even just possesses it, bringing strict rules and penalties. The move aims to keep people safe while the government studies the drug more closely.
2026-12653 — Schedules of Controlled Substances: Placement of Bromazolam in Schedule I; Correction
The DEA fixed a typo in the official chemical name of bromazolam, a drug they put in the strictest Schedule I category starting March 16, 2026. This correction makes the rules clear for everyone involved, especially law enforcement and drug handlers. No new fees or deadlines, just a clean-up to keep things accurate and official.
2026-12140 — Importer of Controlled Substances Application: Scottsdale Research Institute
Scottsdale Research Institute wants to become an official importer of some controlled substances like ibogaine and marijuana. People who make or import these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could affect how these substances are brought into the U.S., but no costs or fees are mentioned yet.
2026-12143 — Importer of Controlled Substances Application: AndersonBrecon, Inc. DBA PCI Pharma Services
AndersonBrecon, Inc. DBA PCI Pharma Services wants to become an official importer of certain controlled substances, including some strong drugs like tetrahydrocannabinols. People and companies involved with these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could impact how these substances are brought into the U.S., but no costs or fees were mentioned yet.
Previous / Next Documents
Previous: 2026-12651 — Certain Frozen Fish Fillets From Vietnam; Determination
The U.S. International Trade Commission decided to keep the extra taxes on frozen fish fillets from Vietnam because removing them could hurt American fish businesses. This means importers will still pay these duties, helping protect U.S. jobs and companies. The decision was finalized in June 2026 and affects anyone buying or selling these fish fillets in the U.S.
Next: 2026-12655 — Notice of Intent To Relocate and Consolidate the Kansas City, Missouri Field Office Into the Kansas City, Kansas Regional Office
HUD plans to move the Kansas City, Missouri Field Office into the nearby Kansas City, Kansas Regional Office, just 5 miles away. This change aims to save money and improve service by combining teams in one spot. The move won’t happen right away—it’ll start after a 90-day review to make sure it’s a smart, cost-effective decision.